Novel cell models for rapid screening of SARS-CoV-2 infection studies


To decipher the pathology of COVID- 19, in vitro cell culture models that can physiologically mimic the viral replication cycle are required. This webinar introduces the A549-AT cell line, generated to meet this need and enable rapid and sensitive monitoring of SARS-CoV-2 replication and facilitating the characterization of viral variants.

REGISTER NOWWhat will you learn?Who may this interest?Speakers

Fill in the form below to register for this panel discussion. If you’re already a member of BioTechniques, your details should be pre-filled so you can register even quicker!

In association with

Automated detection of the virus-induced cytopathic effect can be used to determine the antibody-mediated neutralization efficiency of sera against certain viral variants, as well as for drug screening. The A549-AT cell line could; therefore, offer an added value to future cell-based SARS-CoV-2 diagnostics.

What will you learn?

  • How to measure SARS-CoV-2 cytopathic effects
  • Use of confluency, roughness, fluorescence
  • Sensitive and reproducible evaluation of antivirals

Who may this interest?

  • Researchers
  • Virologists
  • Laboratory diagnostic personel
  • Antibody development


Dr. Marek Widera
Institute for Med. Virology, Goethe-University Frankfurt, University Hospital

2005-2010 Studies (Biology), Heinrich-Heine-University Düsseldorf; 2010-2014 PhD at the University Hospital Düsseldorf, Institute of Virology; 2014-2016 Postdoc University Hospital Essen at the Institute of Virology; 2016-2019 Head of HIV Research Working Group and HIV-1 molecular diagnostics, Institute of Virology at the University Hospital Essen; since 12/2019 Head of Research Working Group for molecular virology with focus on SARS-CoV-2 and HIV-1 at the Institute of Med. Virology, University Hospital of the Goethe University Frankfurt/Main.

Alexander Wilhelm
Institute for Med. Virology, Goethe-University Frankfurt, University Hospital

2011-2014, B.Sc., Molecular Biology, Karl-Franzens-University Graz, Austria; 2014-2017 M.Sc., Molecular and Cellular Biology, Ruprecht-Karls-University Heidelberg, Germany; Since 2017, PhD in the field of acute lymphoblastic leukemia research at the Institute for Pharmaceutical Biology, Goethe University Frankfurt, Germany; Since 04/2020 Researcher with focus on SARS-CoV-2 at the Institute of Med. Virology, University Hospital Frankfurt, Germany.